Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in <i>KRAS</i> Mutant Non-Small Cell Lung Cancer Cell Lines

Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in <i>KRAS</i> Mutant Non-Small Cell Lung Cancer Cell Lines

Background: <i>EGFR</i> mutations are present in approximately 15–50% of non-small cell lung cancer (NSCLC), which are predictive of anti-EGFR therapies. At variance, NSCLC patients harboring <i>KRAS</i> mutations are resistant to those anti-EGFR approaches. Afatinib and alli...

Full description

Bibliographic Details
Main Authors: Renato José da Silva-Oliveira, Izabela Natalia Faria Gomes, Luciane Sussuchi da Silva, André van Helvoort Lengert, Ana Carolina Laus, Matias Eliseo Melendez, Carla Carolina Munari, Fernanda de Paula Cury, Giovanna Barbarini Longato, Rui Manuel Reis
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:International Journal of Molecular Sciences
Subjects:
pan-EGFR
<i>KRAS</i> mutations
mTOR
NSCLC
allitinib
afatinib
Online Access:https://www.mdpi.com/1422-0067/23/14/7774

Internet

https://www.mdpi.com/1422-0067/23/14/7774

Similar Items